US20050202101A1 - Method and composition for preventing or reducing the symptoms of insulin resistance syndrome - Google Patents
Method and composition for preventing or reducing the symptoms of insulin resistance syndrome Download PDFInfo
- Publication number
- US20050202101A1 US20050202101A1 US11/128,727 US12872705A US2005202101A1 US 20050202101 A1 US20050202101 A1 US 20050202101A1 US 12872705 A US12872705 A US 12872705A US 2005202101 A1 US2005202101 A1 US 2005202101A1
- Authority
- US
- United States
- Prior art keywords
- composition
- chromium
- amount
- involves administering
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates generally to a method and composition for preventing or reducing the symptoms of insulin resistance syndrome in a person.
- Insulin resistance is a condition in which the body becomes resistant to its own insulin. The body of the person affected compensates by releasing more insulin, elevating body insulin levels. This elevated insulin level leads to increased risk of a variety of symptoms, including diabetes, obesity, and heart disease.
- Syndrome X appears to be highly prevalent in the obese. Individual elements of Syndrome X (obesity, hypertension, lipid disturbances, and glucose intolerance) are frequently encountered during a typical person's life span, and they tend to be increasingly apparent as people age, usually becoming most prevalent after age 35. Theoretical considerations suggest that insulin resistance may be a primary factor that plays a causative role in the induction of both obesity and diabetes. Atherogenic risk factors associated with obesity and Syndrome X contribute independently to the development of atherosclerotic disease, and risk of a cardiovascular event increases sharply with the burden of risk factors associated with obesity.
- Obesity is clearly the most prevalent metabolic disorder in the United States, and weight control deserves a high priority to curb cardiovascular disease and the associated predisposing conditions, such as lipidemia, hypertension and glucose intolerance.
- the benefits of weight control on the major atherogenic risk factors and the insulin resistance syndrome should provide a strong incentive and rationale for control of obesity.
- non-insulin dependent type II diabetes is highly associated with obesity. It has been reported that healthy persons with elevated insulin levels have increased levels of LDL cholesterol, decreased HDL cholesterol and high blood pressure compared with healthy individuals who have normal insulin levels.
- Diabetes is associated with high blood lipids, hypertension and a tendency of blood platelets to clot, which can block arteries resulting in heart attack or stroke. Diabetes causes a defect in glucose homeostasis. Weight control is a logical first approach to avoid moderate degrees of hypertension, dyslipidemia, glucose tolerance and hyperinsulinemia that constitute Syndrome X.
- Syndrome X To overcome glucose tolerance, patients with syndrome X secrete large amounts of insulin. Treatment of Syndrome X should therefore be aimed at: 1) increasing insulin sensitivity; 2) attenuating day-long hyperinsulinemia; and 3) pharmacologic treatment of the specific manifestations of syndrome X, if lifestyle interventions such as weight loss are not entirely successful.
- the two major lifestyle modulators of insulin action are body weight and physical fitness; the heavier and the more sedentary a patient is, the greater the degree of insulin resistance and compensatory hyperinsulinemia.
- Chromium helps insulin metabolize fat, turn protein into muscle and convert sugar into energy. It is an essential trace element required for normal protein, fat and carbohydrate metabolism. Chromium levels are known to decrease with age, and marginal chromium deficiencies appear to be widespread. Chromium is important for energy production and plays a role in regulating appetite, reducing sugar cravings, and increasing lean body mass.
- Chromium bound niacin or niacin bound chromium (also called chromium nicotinate or chromium polynicotinate) dramatically increases the effectiveness of chromium in a person ingesting it. Normally, chromium is poorly absorbed and utilized by the body. However, researchers have found that the most potent form of chromium in nature is that form bound to the B-vitamin, niacin. Furthermore, previous research discoveries led to the identification of Glucose Tolerance Factor or “GTF”, a biologically active form of chromium that facilitates normal insulin function, which is responsible for normal glucose (blood sugar) metabolism. researchers have found that a particular oxygen-coordinated chromium niacin complex is the most potent form of all, being over eighteen times more potent than the next closest form of chromium bound niacin tested.
- GTF Glucose Tolerance Factor
- Diabetic patients have been found to have lower serum chromium levels and a higher chromium excretion rate. Treatment with chromium bound niacin has been found to improve glucose tolerance in diabetic patients. Dietary trivalent chromium has been shown to have significant beneficial effects on the insulin system.
- chromium supplementation amplifies insulin receptor tyrosine kinase activity, which explains the relationship between chromium and its effects in diabetes. Chromium further reduces vascular smooth muscle calcium loads and thus reduces peripheral vascular resistance in insulin-resistant states.
- the present invention resides in a method for preventing or reducing the symptoms of insulin resistance in a person, the method comprising: identifying a person suffering from or at risk for suffering from the symptoms; and administering a composition comprising an effective amount of chromium bound niacin that, when administered to the person, alleviates, reduces or prevents the symptoms.
- the method preferably incorporates administering a composition comprising between about 50 and about 1,000 ⁇ g chromium bound niacin, preferably in two doses per day.
- the composition incorporates three compounds selected from the following group: ( ⁇ )-hydroxycitric acid, zinc, trans resveratrol, gymnemic acid, selenium, anthocyanidinc, allicin, or saponins.
- the amount of ( ⁇ )-hydroxycitric acid in the composition is between about 250 and about 2,500 mg
- the amount of zinc in the composition is between about 5 and about 50 mg
- the amount of trans-resveratrol in the composition is between about 5 and about 50 mg
- the amount of gymnemic acid in the composition is between about 50 and about 200 mg
- the amount of selenium in the composition is between about 0.025 mg and about 0.1 mg
- the amount of anthocyanidins in the composition is between about 5 and about 50 mg
- the amount of allicin in the composition is between about 2 and about 8 mg
- the amount of saponins in the composition is between about 100 and about 300 mg.
- the present invention also resides in a composition
- a composition comprising chromium bound niacin and three compounds selected from the group consisting of ( ⁇ )-hydroxycitric acid, zinc, trans-resveratrol, gymnemic acid, selenium, anthocyanidins, allicin, and saponins.
- Preferred compositions include amounts of these compounds in the above referenced amounts.
- the present invention resides in a method for preventing or reducing the symptoms of Syndrome X in a person, incorporating a step of identifying a person having the Syndrome, and then administering an amount of chromium bound niacin to the person sufficient to prevent or reduce the symptoms of the Syndrome.
- the present invention also resides in compositions incorporating chromium bound niacin that, when ingested in sufficient quantity by a person, prevent or reduce the symptoms of Syndrome X in the person.
- the method of the present invention involves first identifying a person having Syndrome X.
- a diagnosis of Syndrome X is made based on observing some or all of the following common symptoms: impaired glucose tolerance, hyperinsulinemia, diabetes, hypertriglyceridemia, elevated LD cholesterol, low HDL cholesterol, hypertension, diabetes, and hypertension.
- the person is administered an effective amount of chromium bound niacin, on a daily basis.
- the amount of chromium bound niacin administered to an adult ranges from about 100 to about 1000 ⁇ g per day, taken in two daily doses.
- the chromium bound niacin preferably is administered orally in a variety of forms, including capsule, tablet, beverage, food additive, powder, liquid, or food.
- Preferred aspects of the method of the present invention involve administration of additional compounds along with the chromium bound niacin, including: one or more of the following: ( ⁇ )-hydroxycitric acid; zinc, preferably from zinc methionine; trans-resveratrol; gynmemic acid; selenium; anthocyanidins, preferably from bilberry, blueberry, or grape seed extracts; allicin, preferably from garlic; and saponins, preferably from fenugreek.
- These components work synergistically with the chromium bound niacin to improve its function in alleviating, preventing or reducing the symptoms of Syndrome X.
- compositions administered include any three of the components in the following amounts: 50 to 1000 ⁇ g chromium bound niacin; 250 to 2500 mg ( ⁇ )-hydroxycitric acid; 5 to 50 mg zinc; 1 to 5 mg trans-resveratrol; 50 to 200 mg gymnemic acid; 0.025 to 0.1 mg selenium; 5 to 50 mg anthocyanidins; 2 to 8 mg allicin; and 100 to 300 mg saponins.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Abstract
A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising chromium bound niacin that prevents or reduces the symptoms. Compositions incorporating chromium bound niacin and additional compounds also are disclosed that are particularly effective in preventing or reducing these symptoms.
Description
- This application is a continuation of Ser. No. 10/265,093, titled: Method and Composition for Preventing or Reducing the Symptoms of Insulin Resistance Syndrome, inventors: Debasis Bagchi, Harry G. Preuss and Shil C. Kothari, filed Oct. 4, 2002 (IHEAL-01037US1) which claims priority to U.S. Provisional Patent Application Ser. No. 60/327,896, titled: Method for Preventing or Reducing the Symptoms of Insulin Resistance Syndrome, inventors: Debasis Bagchi, Harry G. Preuss and Shil C. Kothari, filed Oct. 5, 2001 (IHEAL-01037US0). These applications are herein incorporated by reference in their entirety.
- The present invention relates generally to a method and composition for preventing or reducing the symptoms of insulin resistance syndrome in a person.
- An insulin resistance syndrome that has been identified as “Syndrome X” by previous research is a common metabolic disorder affecting more than 75 million Americans to some degree. Insulin resistance is a condition in which the body becomes resistant to its own insulin. The body of the person affected compensates by releasing more insulin, elevating body insulin levels. This elevated insulin level leads to increased risk of a variety of symptoms, including diabetes, obesity, and heart disease.
- Syndrome X appears to be highly prevalent in the obese. Individual elements of Syndrome X (obesity, hypertension, lipid disturbances, and glucose intolerance) are frequently encountered during a typical person's life span, and they tend to be increasingly apparent as people age, usually becoming most prevalent after age 35. Theoretical considerations suggest that insulin resistance may be a primary factor that plays a causative role in the induction of both obesity and diabetes. Atherogenic risk factors associated with obesity and Syndrome X contribute independently to the development of atherosclerotic disease, and risk of a cardiovascular event increases sharply with the burden of risk factors associated with obesity.
- Animal models of Syndrome X, as observed in rats fed high fat diets, exhibit excess accumulation of muscle triglyceride coincident with development of insulin resistance. This also seems to occur in humans; several studies demonstrate increased muscle triglyceride content in insulin resistant states. There is substantial evidence indicating that excess muscle and liver lipid accumulation causes or exacerbates insulin resistance in Syndrome X and in Type II diabetes. Development of strategies to prevent this, therefore, seem worthwhile.
- Avoiding weight gain from adolescence to middle age is known to reduce cardiovascular morbidity and mortality. Despite much debate in the past regarding the influence of obesity on health and the benefits of maintaining normal weight, it is clear that changes in weight correlate to changes in several atherogenic risk factors. Recent perspective studies indicate a continuous graded influence of body mass index (BMI), the ratio of weight expressed in kilograms divide by the height meters squared, on the rate of coronary disease development. Increased risk is evident at BMI levels below average, indicating that moderate obesity can be unhealthy. Central obesity, typically including measurements of waist girth or waist to hip ratio, has been shown to be more metabolically disadvantageous than other forms of obesity and, as a consequence, it is considered a strong predictor of cardiovascular disease.
- The mechanism whereby obesity and weight gain promote atherogenic risk factors and, in turn, cardiovascular disease is well established. Excess body fat has been shown to increase resistance to insulin action and reduce uptake of glucose by peripheral tissues. Abdominal obesity, in particular, is associated with insulin resistance, hyperinsulinemia, a relative deficiency of lipoprotein lipase, elevated triglycerides, reduced HDL-cholesterol and small dense LDL-particles. Obesity may promote increased absorption in the renal tubules, expanding blood volume and inducing an autonomic imbalance that results in hypertension. In addition, insulin resistance often eventuates into glucose intolerance and diabetes which in turn accelerates atherogenesis.
- Obesity is clearly the most prevalent metabolic disorder in the United States, and weight control deserves a high priority to curb cardiovascular disease and the associated predisposing conditions, such as lipidemia, hypertension and glucose intolerance. The benefits of weight control on the major atherogenic risk factors and the insulin resistance syndrome should provide a strong incentive and rationale for control of obesity. There is no other risk factor that affects the cardiovascular risk profile as strongly. It is well known that non-insulin dependent type II diabetes is highly associated with obesity. It has been reported that healthy persons with elevated insulin levels have increased levels of LDL cholesterol, decreased HDL cholesterol and high blood pressure compared with healthy individuals who have normal insulin levels. Diabetes is associated with high blood lipids, hypertension and a tendency of blood platelets to clot, which can block arteries resulting in heart attack or stroke. Diabetes causes a defect in glucose homeostasis. Weight control is a logical first approach to avoid moderate degrees of hypertension, dyslipidemia, glucose tolerance and hyperinsulinemia that constitute Syndrome X.
- To overcome glucose tolerance, patients with syndrome X secrete large amounts of insulin. Treatment of Syndrome X should therefore be aimed at: 1) increasing insulin sensitivity; 2) attenuating day-long hyperinsulinemia; and 3) pharmacologic treatment of the specific manifestations of syndrome X, if lifestyle interventions such as weight loss are not entirely successful. The two major lifestyle modulators of insulin action are body weight and physical fitness; the heavier and the more sedentary a patient is, the greater the degree of insulin resistance and compensatory hyperinsulinemia.
- However, even with control of weight, many people can still develop Syndrome X. Also, many people find controlling their weight to be difficult, and they are unsuccessful in their attempts. Therefore, pharmocological treatments are needed to help reduce the effects of Syndrome X in persons.
- Chromium helps insulin metabolize fat, turn protein into muscle and convert sugar into energy. It is an essential trace element required for normal protein, fat and carbohydrate metabolism. Chromium levels are known to decrease with age, and marginal chromium deficiencies appear to be widespread. Chromium is important for energy production and plays a role in regulating appetite, reducing sugar cravings, and increasing lean body mass.
- Chromium bound niacin or niacin bound chromium (also called chromium nicotinate or chromium polynicotinate) dramatically increases the effectiveness of chromium in a person ingesting it. Normally, chromium is poorly absorbed and utilized by the body. However, researchers have found that the most potent form of chromium in nature is that form bound to the B-vitamin, niacin. Furthermore, previous research discoveries led to the identification of Glucose Tolerance Factor or “GTF”, a biologically active form of chromium that facilitates normal insulin function, which is responsible for normal glucose (blood sugar) metabolism. Researchers have found that a particular oxygen-coordinated chromium niacin complex is the most potent form of all, being over eighteen times more potent than the next closest form of chromium bound niacin tested.
- In 1997, researchers at the University of Texas, Austin, showed that a combination of administration of chromium bound niacin along with exercise in obese women resulted in a significant weight loss in women and also lowered the increase in insulin levels when the women were orally fed glucose. In contrast, those taking chromium picolinate, a different form of chromium, were found to show significant weight gain. In 1999, researchers at Georgetown University Medical Center showed that compared to a placebo, chromium bound niacin caused significant loss of body fat and sparing of muscle (lean body mass) in overweight African-American women. Also, tests on the blood chemistries of the women revealed no significant adverse effects from the ingestion of 600 μg of elemental chromium daily for 2 months. This observation demonstrated the safety of administration of chromium bound niacin at the tested levels.
- In 1994, researchers at Auburn University showed that supplementation with 200 μg of chromium bound niacin significantly lowered moderate levels of cholesterol by an average of 14 percent and improved the ratio of total cholesterol to HDL (“good”) cholesterol by 7 percent in male athletes. In 1995, researchers at Georgetown University Medical Center showed that a combination of chromium bound niacin and soluble fiber (i.e., guar) significantly inhibited sugar-induced high blood pressure in rats. In 1997, researchers at Georgetown University Medical Center showed that chromium bound niacin inhibited sugar-induced high blood pressure, improved long-term blood sugar status and reduced liver and kidney lipid peroxidation in rats. In 2000, researchers at Georgetown University Medical Center showed that a combination of chromium bound niacin and grape seed proanthocyanidin extract significantly lowered both total cholesterol levels and LDL (“bad”) cholesterol levels by 10 and 14 percent, respectively, in people with elevated blood cholesterol levels.
- Diabetic patients have been found to have lower serum chromium levels and a higher chromium excretion rate. Treatment with chromium bound niacin has been found to improve glucose tolerance in diabetic patients. Dietary trivalent chromium has been shown to have significant beneficial effects on the insulin system.
- It has been demonstrated that essential hypertension may be due to insulin perturbations. As high dose chromium supplementation seems nontoxic, chromium may prove to be a useful means to lower blood pressure in some essential hypertensives as well as diabetic hypertensives. It also has been shown that chromium supplementation may prove to be the most useful means to prevent or treat type II diabetes mellitus and related cardiovascular disorders. Chromium supplementation amplifies insulin receptor tyrosine kinase activity, which explains the relationship between chromium and its effects in diabetes. Chromium further reduces vascular smooth muscle calcium loads and thus reduces peripheral vascular resistance in insulin-resistant states.
- Recently, the U.S. Department of Agriculture (USDA) found that many middle-age diabetics could overcome their symptoms by taking a chromium supplement. The USDA's findings suggest that very low chromium intakes may be putting millions of Americans on the road to diabetes (and high blood cholesterol) and that the process could be reversed by supplementing with chromium. A separate study found that marginal chromium loss in male athletes resulting in impaired insulin function can be improved by supplementation with chromium bound niacin.
- However, though the above studies demonstrate that administering chromium bound niacin may serve as a beneficial therapeutic method for reducing or preventing the various symptoms associated with Syndrome X, this has not been entirely effective. Improved methods and compositions, therefore, are necessary to provide for preventing or and reducing the symptoms of Syndrome X in persons. The present invention fulfills this need and provides for further advantages.
- The present invention resides in a method for preventing or reducing the symptoms of insulin resistance in a person, the method comprising: identifying a person suffering from or at risk for suffering from the symptoms; and administering a composition comprising an effective amount of chromium bound niacin that, when administered to the person, alleviates, reduces or prevents the symptoms. The method preferably incorporates administering a composition comprising between about 50 and about 1,000 μg chromium bound niacin, preferably in two doses per day.
- In a preferred aspect of the method, the composition incorporates three compounds selected from the following group: (−)-hydroxycitric acid, zinc, trans resveratrol, gymnemic acid, selenium, anthocyanidinc, allicin, or saponins.
- Preferably, if present, the amount of (−)-hydroxycitric acid in the composition is between about 250 and about 2,500 mg, the amount of zinc in the composition is between about 5 and about 50 mg, the amount of trans-resveratrol in the composition is between about 5 and about 50 mg, the amount of gymnemic acid in the composition is between about 50 and about 200 mg, the amount of selenium in the composition is between about 0.025 mg and about 0.1 mg, the amount of anthocyanidins in the composition is between about 5 and about 50 mg, the amount of allicin in the composition is between about 2 and about 8 mg, and the amount of saponins in the composition is between about 100 and about 300 mg.
- The present invention also resides in a composition comprising chromium bound niacin and three compounds selected from the group consisting of (−)-hydroxycitric acid, zinc, trans-resveratrol, gymnemic acid, selenium, anthocyanidins, allicin, and saponins. Preferred compositions include amounts of these compounds in the above referenced amounts.
- The present invention resides in a method for preventing or reducing the symptoms of Syndrome X in a person, incorporating a step of identifying a person having the Syndrome, and then administering an amount of chromium bound niacin to the person sufficient to prevent or reduce the symptoms of the Syndrome. The present invention also resides in compositions incorporating chromium bound niacin that, when ingested in sufficient quantity by a person, prevent or reduce the symptoms of Syndrome X in the person.
- The method of the present invention involves first identifying a person having Syndrome X. A diagnosis of Syndrome X is made based on observing some or all of the following common symptoms: impaired glucose tolerance, hyperinsulinemia, diabetes, hypertriglyceridemia, elevated LD cholesterol, low HDL cholesterol, hypertension, diabetes, and hypertension. Then, the person is administered an effective amount of chromium bound niacin, on a daily basis. Preferably, the amount of chromium bound niacin administered to an adult ranges from about 100 to about 1000 μg per day, taken in two daily doses. The chromium bound niacin preferably is administered orally in a variety of forms, including capsule, tablet, beverage, food additive, powder, liquid, or food.
- Preferred aspects of the method of the present invention involve administration of additional compounds along with the chromium bound niacin, including: one or more of the following: (−)-hydroxycitric acid; zinc, preferably from zinc methionine; trans-resveratrol; gynmemic acid; selenium; anthocyanidins, preferably from bilberry, blueberry, or grape seed extracts; allicin, preferably from garlic; and saponins, preferably from fenugreek. These components work synergistically with the chromium bound niacin to improve its function in alleviating, preventing or reducing the symptoms of Syndrome X. Particularly preferred compositions administered include any three of the components in the following amounts: 50 to 1000 μg chromium bound niacin; 250 to 2500 mg (−)-hydroxycitric acid; 5 to 50 mg zinc; 1 to 5 mg trans-resveratrol; 50 to 200 mg gymnemic acid; 0.025 to 0.1 mg selenium; 5 to 50 mg anthocyanidins; 2 to 8 mg allicin; and 100 to 300 mg saponins.
- Studies were conducted to evaluate the efficacy of a combination of natural products, including chromium bound niacin, on lowering high blood pressure, one of the particular symptoms commonly associated with Syndrome X. One half of a group of 100 normotensive rats were fed a diet containing the following: chromium nicotinate at a human equivalency dosage of 400 μg of elemental chromium (marketed under the brand name ChromeMate by InterHealth Nutraceuticals of Benicia, Calif.), zinc methionine (marketed under the brand name OptiZinc by InterHealth Nutraceuticals), and grape seed extract incorporating proanthocyanidins (marketed under the brand name ActiVin by InterHealth Nutraceuticals). The rats that were placed on diets containing supplemental chromium nicotinate had significantly lowered blood pressure and lipid peroxidation in their livers and kidneys than rats fed normal diets. Sugar-induced hypertension also was reduced in the rats, along with hepatic and renal lipid peroxidation and glycosylated hemoglobin levels.
- Although the invention has been disclosed in detail with reference only to the preferred embodiments, those skilled in the art will appreciate that additional methods and compositions can be made without departing from the scope of the invention.
Claims (22)
1. A method for reducing a symptom of syndrome X in a person, the method comprising:
(a) identifying a person suffering from or at risk for suffering from the symptom;
(b) administering a composition comprising an effective amount of chromium; and one or more other compounds selected from the group consisting of (−)-hydroxycitric acid, zinc, trans-resveratrol, gymnemic acid, selenium, an anthocyanidin, allicin, and a saponin; and
(c) testing for a reduction in said symptom.
2. The method of claim 1 , where in step (c) the symptom is selected from the group consisting of tendency of blood platelets to clot, elevated blood pressure, obesity, central obesity, elevated body mass index, insulin resistance, hyperinsulinemia, hypertension, serum glucose, glucose tolerance, glucose intolerance, lipoprotein lipase deficiency, liver lipid peroxidation, kidney lipid peroxidation, dyslipidemia, hyper-lipidemia, lipid accumulation, elevated triglycerides, reduced high density lipoprotein (HDL), increased low density lipoprotein (LDL) and the LDL to HDL ratio.
3. The method of claim 1 , wherein step (b) involves administering the composition in two doses per day.
4. The method of claim 1 , wherein said chromium is chromium bound to niacin.
5. The method of claim 1 , wherein said other compound is (−)-hydroxycitric acid.
6. The method of claim 1 , wherein said other compound is zinc.
7. The method of claim 1 , wherein said other compound is trans-resveratrol.
8. The method of claim 1 , wherein said other compound is gymnemic acid.
9. The method of claim 1 , wherein said other compound is selenium.
10. The method of claim 1 , wherein said other compound is an anthocyanidin.
11. The method of claim 1 , wherein said other compound is allicin.
12. The method of claim 1 , step said other compound is a saponin.
13. The method of claim 4 , wherein step (b) involves administering the composition comprising an amount between:
about 50 μg; and
about 1000 μg of chromium bound to niacin.
14. The method of claim 5 , wherein step (b) involves administering the composition comprising an amount between:
about 250 mg; and
about 3000 mg of (−)-hydroxycitric acid.
15. The method of claim 6 , wherein step (b) involves administering the composition comprising an amount between:
about 5 mg; and
about 50 mg of zinc.
16. The method of claim 7 , wherein step (b) involves administering the composition comprising an amount between:
about 5 mg; and
about 100 mg of trans-resveratrol.
17. The method of claim 8 , wherein step (b) involves administering the composition comprising an amount between:
about 50 mg; and
about 200 mg of gymnemic acid.
18. The method of claim 9 , wherein step (b) involves administering the composition comprising an amount between:
about 0.025 mg; and
about 0.1 mg of selenium.
19. The method of claim 10 , step (b) involves administering the composition comprising an amount between:
about 5 mg; and
about 100 mg of an anthocyanidin.
20. The method of claim 11 , wherein step (b) involves administering the composition comprising an amount between:
about 2 mg; and
about 8 mg of allicin.
21. The method of claim 12 , wherein step (b) involves administering the composition comprising an amount between:
about 100 mg; and
about 300 mg of saponins.
22. A method for reducing excess liver and/or muscle lipid accumulation comprising:
(a) identifying a person suffering from or at risk for suffering from the symptoms;
(b) administering a composition comprising an effective amount of chromium bound niacin, (−)-hydroxycitric acid, gymnemic acid; and one or more other compounds selected from the group consisting of zinc, trans-resveratrol, selenium, an anthocyanidin, allicin, and a saponin; and
(c) testing for a reduction in liver and/or muscle lipid accumulation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/128,727 US20050202101A1 (en) | 2001-10-05 | 2005-05-13 | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32789601P | 2001-10-05 | 2001-10-05 | |
US10/265,093 US7119110B2 (en) | 2001-10-05 | 2002-10-04 | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
US11/128,727 US20050202101A1 (en) | 2001-10-05 | 2005-05-13 | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/265,093 Continuation US7119110B2 (en) | 2001-10-05 | 2002-10-04 | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050202101A1 true US20050202101A1 (en) | 2005-09-15 |
Family
ID=23278548
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/265,093 Expired - Lifetime US7119110B2 (en) | 2001-10-05 | 2002-10-04 | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
US11/009,266 Expired - Lifetime US7153877B2 (en) | 2001-10-05 | 2004-12-09 | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
US11/128,727 Abandoned US20050202101A1 (en) | 2001-10-05 | 2005-05-13 | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/265,093 Expired - Lifetime US7119110B2 (en) | 2001-10-05 | 2002-10-04 | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
US11/009,266 Expired - Lifetime US7153877B2 (en) | 2001-10-05 | 2004-12-09 | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
Country Status (9)
Country | Link |
---|---|
US (3) | US7119110B2 (en) |
EP (1) | EP1438038A4 (en) |
JP (1) | JP2005508371A (en) |
AU (1) | AU2002351456B2 (en) |
CA (1) | CA2462158A1 (en) |
IL (1) | IL161186A0 (en) |
MX (1) | MXPA04003233A (en) |
WO (1) | WO2003039535A1 (en) |
ZA (1) | ZA200402688B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080003303A1 (en) * | 2006-05-31 | 2008-01-03 | Interhealth Nutraceuticals Inc. | Nutraceutical treatments for diabetic and non-diabetic wound healing |
US20100062087A1 (en) * | 2006-06-02 | 2010-03-11 | Interhealth Nutraceuticals, Inc. | Nutraceutical Treatments for Diabetic and Non-Diabetic Wound Healing |
IT201700032960A1 (en) * | 2017-03-24 | 2018-09-24 | Akademy Pharma S R L | NUTRACEUTICAL COMPOUND FOR THE TREATMENT OF THE EXCESS OF WEIGHT AND MODERATE HYPERCOLESTEROLEMIA AND DISGLICEMIA |
WO2021247289A1 (en) * | 2020-06-02 | 2021-12-09 | Glykon Technologies Group, Llc | Reducing triglyceride levels and cortisol levels with pharmaceutical preparations |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001527022A (en) | 1997-07-14 | 2001-12-25 | ラジュ、ジー・ガンガ | Hydroxycitric acid compositions, supplements and supplements and foods made therefrom and methods of using them in reducing body weight |
US20040157929A1 (en) * | 2002-04-01 | 2004-08-12 | Ohia Sunny E. | Method for increasing serotonin levels in a person by administration of a composition incorporating(-)hydroxycitric acid, and related compositions thereof |
US7119110B2 (en) | 2001-10-05 | 2006-10-10 | Interhealth Nutraceuticals Incorporated | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
US20030119913A1 (en) * | 2001-12-20 | 2003-06-26 | Ohia Sunny E. | Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof |
ES2283756T3 (en) * | 2002-03-01 | 2007-11-01 | Novagali Pharma Sa | PHARMACO ADMINISTRATION ADMINISTRATION SYSTEMS FOR TAXOIDS. |
US7977049B2 (en) * | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
TW200427447A (en) * | 2003-03-21 | 2004-12-16 | Interhealth Nutraceuticals Inc | Method and composition for decreasing ghrelin levels |
AU2004253579B2 (en) * | 2003-07-01 | 2010-12-23 | Biomol International L.P. | Sirt1 modulators for manipulating cells/organism lifespan/stress response |
US8017634B2 (en) * | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
WO2005065667A2 (en) * | 2003-12-29 | 2005-07-21 | President And Fellows Of Harvard College | Compositions for treating or preventing obesity and insulin resistance disorders |
US20050215644A1 (en) * | 2004-03-19 | 2005-09-29 | Interhealth Nutraceuticals, Inc. | Methods for increasing neurotransmitter levels using hydroxycitric acid |
PT1577320E (en) | 2004-03-19 | 2012-10-30 | Pasteur Institut | Peptides derived from human bplp protein, polynucleotides coding for said peptides and antibodies directed against said peptides |
EP1734963A4 (en) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | Method of treating men with metabolic and anthropometric disorders |
CA2570121A1 (en) * | 2004-06-16 | 2006-01-19 | President And Fellows Of Harvard College | Methods and compositions for modulating bax-ku70-mediated apoptosis |
JP2006273834A (en) * | 2004-06-28 | 2006-10-12 | Kao Corp | Ampk activator |
EP1762234A4 (en) * | 2004-06-28 | 2010-05-05 | Kao Corp | Ampk activator |
WO2006004722A2 (en) * | 2004-06-30 | 2006-01-12 | Biomol Research Laboratories, Inc. | Compositions and methods for selectively activating human sirtuins |
US20060029642A1 (en) * | 2004-08-03 | 2006-02-09 | Dusan Miljkovic | Methods and compositions for improved chromium complexes |
WO2006138418A2 (en) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
US20070149466A1 (en) * | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
NZ567332A (en) * | 2005-09-28 | 2011-05-27 | Univ California | Method for lowering blood pressure in pre-hypertensive individuals and/or individuals with metabolic syndrome |
US7912716B2 (en) * | 2005-10-06 | 2011-03-22 | Sony Online Entertainment Llc | Generating words and names using N-grams of phonemes |
JP2007126390A (en) * | 2005-11-02 | 2007-05-24 | Mercian Corp | Agent for reducing blood glucose level |
JP5045879B2 (en) * | 2006-06-07 | 2012-10-10 | 株式会社龍泉堂 | A mixture having an effect of improving insulin resistance, an effect of suppressing weight gain, and an effect of preventing and improving fatty liver |
TW201002332A (en) * | 2008-07-07 | 2010-01-16 | Univ Nat Chunghsing | Composition for preventing and controlling fatty liver disease |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
JP5557845B2 (en) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | Novel cyclic benzimidazole derivatives useful as antidiabetic agents |
US20100323031A1 (en) * | 2009-06-22 | 2010-12-23 | Glykon Technologies Group, Llc | Synergistic combination to enhance blood glucose and insulin metabolism |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
JP5728099B2 (en) | 2011-02-25 | 2015-06-03 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as antidiabetic agents |
US9527875B2 (en) | 2012-08-02 | 2016-12-27 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
RU2015140066A (en) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | ANTI-DIABETIC BICYCLIC COMPOUNDS |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CA2953243A1 (en) | 2014-06-12 | 2015-12-17 | Four LLC | Sweet taste receptor antagonist compositions |
CN106491641A (en) * | 2016-10-28 | 2017-03-15 | 乌林奇 | A kind of compsn. consisting of influenza virus surface of targeting preventing and treating cerebral thrombosiss and application |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5266560A (en) * | 1988-06-03 | 1993-11-30 | Thomas Research Corporation | Pharmaceutical insulin-potentiating CR(III) complexes with GTF-like activity |
US5480657A (en) * | 1993-10-27 | 1996-01-02 | Allen; Ann De Wees T. | Composition comprising caffeine chromium and fructose for weight control and use thereof |
US5536516A (en) * | 1994-08-24 | 1996-07-16 | Renaissance Herbs, Inc. | Hydroxycitric acid concentrate and food products prepared therefrom |
US5612039A (en) * | 1994-03-14 | 1997-03-18 | Nini E. Policappelli | Dietary supplement |
US5626849A (en) * | 1995-06-07 | 1997-05-06 | Reliv International, Inc. | Weight loss composition for burning and reducing synthesis of fats |
US5716976A (en) * | 1996-03-13 | 1998-02-10 | Bernstein; Richard K. | Method of treatment for carbohydrate addiction |
US5783603A (en) * | 1995-05-15 | 1998-07-21 | Sabinsa Corporation | Potassium hydroxycitrate for the suppression of appetite and induction of weight loss |
US5905075A (en) * | 1998-08-28 | 1999-05-18 | Ambi Inc. | Chromium nicotinate compositions and uses thereof |
US6034125A (en) * | 1997-07-28 | 2000-03-07 | Mcleod; Malcolm N. | Method of treating depression using chromium |
US6207714B1 (en) * | 1999-09-14 | 2001-03-27 | Dallas L. Clouatre | Methods and pharmaceutical preparations for improving glucose metabolism with (−)-hydroxycitric acid |
US6217898B1 (en) * | 1995-12-15 | 2001-04-17 | Sigma-Tau Healthscience S.P.A. | Pharmaceutical composition comprising carnitine or alkanoyl L-carnitine, for the prevention and treatment of diseases brought about by lipid metabolism disorders |
US6258848B1 (en) * | 1998-07-31 | 2001-07-10 | Mount Sinai Hospital | Methods and compositions for increasing insulin sensitivity |
US6383482B1 (en) * | 2000-08-24 | 2002-05-07 | Vitacost.Com, Inc. | Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus |
US6399089B1 (en) * | 2000-05-15 | 2002-06-04 | A. Glenn Braswell | Compositions and methods for regulating metabolism and balancing body weight |
US6420350B1 (en) * | 2001-01-18 | 2002-07-16 | Goen Group, Inc. | Weight loss product |
US6441041B1 (en) * | 2001-06-20 | 2002-08-27 | Dallas L. Clouatre | (-)-hydroxycitric acid for the prevention of osteoporosis |
US6447807B1 (en) * | 1999-09-14 | 2002-09-10 | Dallas L. Clouatre | Potassium (-)-hydroxycitric acid methods for pharmaceutical preparations for stable and controlled delivery |
US6476071B1 (en) * | 2001-05-07 | 2002-11-05 | Dallas L. Clouatre | Correcting polymorphic metabolic dysfunction with (−)-hydroxycitric acid |
US6482858B1 (en) * | 2001-06-20 | 2002-11-19 | Dallas L Clouatre | (−)-hydroxycitric acid for wound healing and immunomodulation |
US6809115B2 (en) * | 2000-09-21 | 2004-10-26 | Nutrition 21, Inc. | Methods and compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
US6967030B2 (en) * | 2003-01-14 | 2005-11-22 | Wright Jonathan V | Formulation for insulin and glucose control |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3764692A (en) | 1970-09-30 | 1973-10-09 | Hoffmann La Roche | Method of treating obesity |
US4954492A (en) * | 1983-07-08 | 1990-09-04 | The William Seroy Group | Synthetic GTF chromium material for decreasing blood lipid levels and process therefor |
US4923855A (en) | 1983-07-08 | 1990-05-08 | The William Seroy Group | Synthetic GTF chromium material and process therefor |
US5194615A (en) | 1983-07-08 | 1993-03-16 | The William Seroy Group | Synthetic GTF chromium nicotinate material and its preparation |
JPS62236469A (en) | 1986-04-04 | 1987-10-16 | Yasutake Hichi | Low-calorie food and drink |
US5543405A (en) | 1993-10-22 | 1996-08-06 | Keown; Wendy J. | Composition and method for weight reduction and long term management of obesity |
US5567424A (en) | 1994-06-10 | 1996-10-22 | Reliv International, Inc. | Fiber, antioxidant, herbal and enzyme supplemented beverage composition for human consumption |
US6352713B1 (en) | 1999-12-01 | 2002-03-05 | Drugtech Corporation | Nutritional composition |
US20040196181A1 (en) * | 1994-09-22 | 2004-10-07 | Huston Charles D. | Method and apparatus for message display on a golf course |
EP0714663A3 (en) | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug response by a serotonin 1A receptor antagonist |
FI120290B (en) | 1996-12-30 | 2009-09-15 | Mirador Res Oy Ltd | A method for preparing seasoning compound, food ingredient, and food compositions that lower serum cholesterol |
JP2001511153A (en) | 1997-02-04 | 2001-08-07 | ブイ. コスバブ,ジョン | Compositions and methods for prevention and treatment of vascular degenerative diseases |
US5962030A (en) | 1997-03-07 | 1999-10-05 | Akesis Pharmaceuticals, Inc. | Dietary supplement and method of treatment for diabetic control |
JP3736776B2 (en) | 1997-03-25 | 2006-01-18 | 宝ホールディングス株式会社 | New calcium composition |
US5981510A (en) | 1997-04-15 | 1999-11-09 | Yaizu Suisankagaku Industry Co., Ltd. | Method for treating and improving diabetes |
US5911992A (en) | 1997-06-12 | 1999-06-15 | A. Glenn Braswell | Method for controlling weight with hypericum perforatum and garcinia cambogia |
JP2001527022A (en) | 1997-07-14 | 2001-12-25 | ラジュ、ジー・ガンガ | Hydroxycitric acid compositions, supplements and supplements and foods made therefrom and methods of using them in reducing body weight |
US6160172A (en) * | 1997-08-27 | 2000-12-12 | Vittal Mallya Scientific Research Foundation | Soluble double metal salt of group IA and IIA of (-) hydroxycitric acid, process of preparing the same and its use in beverages and other food products without effecting their flavor and properties |
DE69935206T2 (en) | 1998-02-23 | 2007-10-31 | Taiyo Kagaku Co., Ltd., Yokkaichi | THEANIN-LEGGING COMPOSITION |
US6048846A (en) | 1998-02-26 | 2000-04-11 | Cochran; Timothy M. | Compositions used in human treatment |
WO2000012080A1 (en) | 1998-09-01 | 2000-03-09 | Amway Corporation | Diet composition and method of weight management |
AU2851799A (en) | 1999-02-18 | 2000-09-04 | Vittal Mallya Scientific Research Foundation | Soluble double metal salt of group ia and iia of (-) hydroxycitric acid |
AU4326500A (en) | 1999-03-26 | 2000-10-16 | Akesis Pharmaceuticals, Inc. | Beverages for treatment of glucose metabolism disorders |
US20030220329A1 (en) | 1999-09-17 | 2003-11-27 | Duke University | Method of improving beta-adrenergic receptor function |
AU2437101A (en) | 1999-12-16 | 2001-06-25 | Harry Siskind | Nutritional composition, methods of producing said composition and methods of using said composition |
US6291533B1 (en) | 1999-12-22 | 2001-09-18 | Vitamerica, Inc. | Dietary supplements for each specific blood type |
US7015250B2 (en) | 2000-02-09 | 2006-03-21 | Glykon Technologies Group, Llc | Methods and pharmaceutical preparations for normalizing blood pressure with (-)-hydroxycitric acid |
US6579866B2 (en) | 2000-12-28 | 2003-06-17 | Mccleary Larry | Composition and method for modulating nutrient partitioning |
US20040157929A1 (en) | 2002-04-01 | 2004-08-12 | Ohia Sunny E. | Method for increasing serotonin levels in a person by administration of a composition incorporating(-)hydroxycitric acid, and related compositions thereof |
EP1379261A4 (en) | 2001-03-30 | 2004-09-08 | Interhealth Nutraceuticals Inc | Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof |
US6638542B2 (en) | 2001-09-20 | 2003-10-28 | Nutricia N.V. | Reducing appetite in mammals by administering procyanidin and hydroxycitric acid |
US7119110B2 (en) | 2001-10-05 | 2006-10-10 | Interhealth Nutraceuticals Incorporated | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
US20030119913A1 (en) | 2001-12-20 | 2003-06-26 | Ohia Sunny E. | Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof |
US7507421B2 (en) | 2002-04-30 | 2009-03-24 | Unibar Corporation | Hydroxycitric acid salt composition and method of making |
TW200427447A (en) | 2003-03-21 | 2004-12-16 | Interhealth Nutraceuticals Inc | Method and composition for decreasing ghrelin levels |
-
2002
- 2002-10-04 US US10/265,093 patent/US7119110B2/en not_active Expired - Lifetime
- 2002-10-07 EP EP02786372A patent/EP1438038A4/en not_active Withdrawn
- 2002-10-07 JP JP2003541826A patent/JP2005508371A/en active Pending
- 2002-10-07 IL IL16118602A patent/IL161186A0/en unknown
- 2002-10-07 CA CA002462158A patent/CA2462158A1/en not_active Abandoned
- 2002-10-07 WO PCT/US2002/031987 patent/WO2003039535A1/en not_active Application Discontinuation
- 2002-10-07 AU AU2002351456A patent/AU2002351456B2/en not_active Ceased
- 2002-10-07 MX MXPA04003233A patent/MXPA04003233A/en active IP Right Grant
-
2004
- 2004-04-06 ZA ZA200402688A patent/ZA200402688B/en unknown
- 2004-12-09 US US11/009,266 patent/US7153877B2/en not_active Expired - Lifetime
-
2005
- 2005-05-13 US US11/128,727 patent/US20050202101A1/en not_active Abandoned
Patent Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5266560A (en) * | 1988-06-03 | 1993-11-30 | Thomas Research Corporation | Pharmaceutical insulin-potentiating CR(III) complexes with GTF-like activity |
US5480657A (en) * | 1993-10-27 | 1996-01-02 | Allen; Ann De Wees T. | Composition comprising caffeine chromium and fructose for weight control and use thereof |
US5612039A (en) * | 1994-03-14 | 1997-03-18 | Nini E. Policappelli | Dietary supplement |
US5536516A (en) * | 1994-08-24 | 1996-07-16 | Renaissance Herbs, Inc. | Hydroxycitric acid concentrate and food products prepared therefrom |
US5656314A (en) * | 1994-08-24 | 1997-08-12 | Moffett; Scott Alexander | Hydroxycitric acid concentrate and food products prepared therefrom |
US5783603A (en) * | 1995-05-15 | 1998-07-21 | Sabinsa Corporation | Potassium hydroxycitrate for the suppression of appetite and induction of weight loss |
US5626849A (en) * | 1995-06-07 | 1997-05-06 | Reliv International, Inc. | Weight loss composition for burning and reducing synthesis of fats |
US6217898B1 (en) * | 1995-12-15 | 2001-04-17 | Sigma-Tau Healthscience S.P.A. | Pharmaceutical composition comprising carnitine or alkanoyl L-carnitine, for the prevention and treatment of diseases brought about by lipid metabolism disorders |
US5716976A (en) * | 1996-03-13 | 1998-02-10 | Bernstein; Richard K. | Method of treatment for carbohydrate addiction |
US6034125A (en) * | 1997-07-28 | 2000-03-07 | Mcleod; Malcolm N. | Method of treating depression using chromium |
US6258848B1 (en) * | 1998-07-31 | 2001-07-10 | Mount Sinai Hospital | Methods and compositions for increasing insulin sensitivity |
US5905075A (en) * | 1998-08-28 | 1999-05-18 | Ambi Inc. | Chromium nicotinate compositions and uses thereof |
US6207714B1 (en) * | 1999-09-14 | 2001-03-27 | Dallas L. Clouatre | Methods and pharmaceutical preparations for improving glucose metabolism with (−)-hydroxycitric acid |
US6447807B1 (en) * | 1999-09-14 | 2002-09-10 | Dallas L. Clouatre | Potassium (-)-hydroxycitric acid methods for pharmaceutical preparations for stable and controlled delivery |
US6399089B1 (en) * | 2000-05-15 | 2002-06-04 | A. Glenn Braswell | Compositions and methods for regulating metabolism and balancing body weight |
US6383482B1 (en) * | 2000-08-24 | 2002-05-07 | Vitacost.Com, Inc. | Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus |
US6809115B2 (en) * | 2000-09-21 | 2004-10-26 | Nutrition 21, Inc. | Methods and compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
US6420350B1 (en) * | 2001-01-18 | 2002-07-16 | Goen Group, Inc. | Weight loss product |
US6476071B1 (en) * | 2001-05-07 | 2002-11-05 | Dallas L. Clouatre | Correcting polymorphic metabolic dysfunction with (−)-hydroxycitric acid |
US6441041B1 (en) * | 2001-06-20 | 2002-08-27 | Dallas L. Clouatre | (-)-hydroxycitric acid for the prevention of osteoporosis |
US6482858B1 (en) * | 2001-06-20 | 2002-11-19 | Dallas L Clouatre | (−)-hydroxycitric acid for wound healing and immunomodulation |
US6967030B2 (en) * | 2003-01-14 | 2005-11-22 | Wright Jonathan V | Formulation for insulin and glucose control |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080003303A1 (en) * | 2006-05-31 | 2008-01-03 | Interhealth Nutraceuticals Inc. | Nutraceutical treatments for diabetic and non-diabetic wound healing |
US7887848B2 (en) | 2006-05-31 | 2011-02-15 | Interhealth Nutraceuticals, Inc. | Nutraceutical treatments for diabetic and non-diabetic wound healing |
US20100062087A1 (en) * | 2006-06-02 | 2010-03-11 | Interhealth Nutraceuticals, Inc. | Nutraceutical Treatments for Diabetic and Non-Diabetic Wound Healing |
IT201700032960A1 (en) * | 2017-03-24 | 2018-09-24 | Akademy Pharma S R L | NUTRACEUTICAL COMPOUND FOR THE TREATMENT OF THE EXCESS OF WEIGHT AND MODERATE HYPERCOLESTEROLEMIA AND DISGLICEMIA |
EP3378335A1 (en) * | 2017-03-24 | 2018-09-26 | Akademy Pharma S.r.l. | Nutraceutical compound for the treatment of excess of weight and moderate hypercholesterolemia and dysglycemia |
WO2021247289A1 (en) * | 2020-06-02 | 2021-12-09 | Glykon Technologies Group, Llc | Reducing triglyceride levels and cortisol levels with pharmaceutical preparations |
US11766415B2 (en) | 2020-06-02 | 2023-09-26 | Glykon Technologies Group, Llc | Reducing triglyceride levels and cortisol levels with pharmaceutical preparations |
Also Published As
Publication number | Publication date |
---|---|
US20050100614A1 (en) | 2005-05-12 |
US7119110B2 (en) | 2006-10-10 |
EP1438038A1 (en) | 2004-07-21 |
IL161186A0 (en) | 2004-08-31 |
US20030133992A1 (en) | 2003-07-17 |
US7153877B2 (en) | 2006-12-26 |
EP1438038A4 (en) | 2005-09-21 |
JP2005508371A (en) | 2005-03-31 |
ZA200402688B (en) | 2005-02-08 |
CA2462158A1 (en) | 2003-05-15 |
WO2003039535A1 (en) | 2003-05-15 |
AU2002351456B2 (en) | 2006-11-30 |
MXPA04003233A (en) | 2005-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7153877B2 (en) | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome | |
AU2002351456A1 (en) | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome | |
US10583168B1 (en) | Nutritional supplements including cardiovascular support components | |
AU2002211452B2 (en) | Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases | |
Vasques et al. | Evaluation of the pharmacotherapeutic efficacy of Garcinia cambogia plus Amorphophallus konjac for the treatment of obesity | |
AU2002364213B2 (en) | Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors | |
US6203819B1 (en) | Dietary supplement and method of treatment for diabetic control | |
Levin et al. | Comparison of psyllium hydrophilic mucilloid and cellulose as adjuncts to a prudent diet in the treatment of mild to moderate hypercholesterolemia | |
US20050214384A1 (en) | Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance | |
US20090035397A1 (en) | Methods and compositions for improving cardiovascular risk factors and metabolic risk factors that cause syndrome x | |
PT1397148E (en) | Chromium/biotin treatment of dyslipidemia | |
Odeh et al. | Natural antioxidants for the prevention of atherosclerosis | |
US20040186181A1 (en) | Method and composition for decreasing ghrelin levels | |
Pennell | Optimizing medical management of patients with pre–end-stage renal disease | |
US20030039708A1 (en) | Non-ma huang herb weight loss product | |
Passa | Insulin resistance and hypertension | |
JPH05336923A (en) | Use of product containing chromium, vitamin e and vitamin c for controlling metabolism of carbohydrate and lipid | |
US6500469B1 (en) | Methods and compositions for reducing cholesterol levels using a proanthocyanidin and niacin-bound chromium complex | |
Katholi et al. | Metabolic and Renal Protective Benefits of Magnesium Supplementation in the Long-Term Management of Patients with Type 2 Diabetes Mellitus | |
US20070072910A1 (en) | Compositions and methods for lowering plasma concentrations of low density lipoproteins in humans | |
Levy | Currently available lipid-lowering agents | |
AU2007202775A1 (en) | Compositions incorporating (-)- hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors | |
Stott | The role of HDL-C in diabetes and the metabolic syndrome | |
KUPECZ | Metformin: An Antihyperglycemic Drug for Non–Insulin-Dependent Diabetes Mellitus | |
Wood | The effects of a carbohydrate restricted diet with and without supplemental soluble fiber on cardiovascular risk and lipoprotein metabolism in men |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |